Investigate interactive roles of environmental, behavioral and genetic factors on racial disparities in breast cancer outcomes
研究环境、行为和遗传因素对乳腺癌结果种族差异的交互作用
基本信息
- 批准号:10655049
- 负责人:
- 金额:$ 11.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-01 至 2026-08-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdministrative SupplementAfrican AmericanAgeAll of Us Research ProgramBehaviorBehavioralBehavioral GeneticsBiological MarkersBiomedical ResearchBody mass indexBreast Cancer PatientCaregiversCharacteristicsCommunitiesComplexComputer softwareConsensusDataData SetDatabasesDeath RateElectronic Health RecordEnvironmentEnvironmental Risk FactorEthnic OriginEtiologyGene ExpressionGeneticGenetic DatabasesGenetic Predisposition to DiseaseHealthHealth Disparities ResearchHealthcareHispanic PopulationsIncidenceIndividualInternetInterventionKnowledgeLinkMalignant NeoplasmsMeasurementMeasuresMediationMethodologyMethodsModelingOutcomeParticipantPatientsPhysical activityPlayPollutionProviderPublic HealthQuality of lifeRaceRecurrenceReduce health disparitiesRegistriesReportingResearchResearch PersonnelRisk FactorsRoleSmoking BehaviorStatistical MethodsSurveysTestingThe Cancer Genome AtlasUnited StatesVital StatusWomananalytical toolapplication programming interfacebreast cancer progressioncancer health disparitydata registrydemographicsdesigndisparity reductionepidemiology studyfollow-upgenetic informationhealth datahealth disparityhealth related quality of lifeimprovedmalignant breast neoplasmneoplasm registrynovelpersonalized medicineprecision medicineracial and ethnic disparitiesracial disparityrisk variantsocial determinantstreatment risktreatment strategytriple-negative invasive breast carcinomatumortumor progression
项目摘要
Project Summary:
Health disparities exist widely in the breast cancer outcomes (incidence, survival, and quality-of-life). When
compared with white women, African American women have higher recurrence and death rates from breast
cancer although they have a lower incidence rate. It is well established that both community and individual level
risk factors play important roles in breast cancer outcomes. In our previous studies, we have developed a
mediation analysis method to identify new biomarkers that contribute to health disparities in triple-negative breast
cancer (TNBC). We also developed a new multilevel mediation analysis method that allows for longitudinal
assessments of both residential environments and individual risk factors to be jointly utilized in determining the
mechanistic link between race and health outcomes. By including measures of individual and environmental
factors, our methods are capable of explaining existing disparities in health outcomes.In this project, we aim to
utilize the comprehensive database collected by the All of Us project to investigate the observed racial disparities
in breast cancer outcomes. Using the novel multilevel mediation analysis method, we will identify modifiable
factors that can explain the racial disparities observed in breast cancer outcomes. The risk factors to be
considered include measures at both the environmental (e.g. pollution measurements) and individual levels (e.g.,
smoking behavior and gene expressions). The information will help caregivers design precision medicine and
policymakers evaluate interventions that aim at improving treatment and reducing health disparities. We have
implemented our method as an R package (mlma) to provide the research community with open access to
software for performing multilevel mediation analysis. We plan to further develop an API for an interactive web
implementation of the software so that all researchers can use the method without the programming requirement.
项目概要:
乳腺癌结果(发病率、生存率和生活质量)广泛存在健康差异。什么时候
与白人女性相比,非洲裔美国女性乳腺癌复发率和死亡率更高
癌症,尽管它们的发病率较低。众所周知,社区和个人层面
危险因素在乳腺癌结果中发挥着重要作用。在我们之前的研究中,我们开发了一个
中介分析方法识别导致三阴性乳腺癌健康差异的新生物标志物
癌症(TNBC)。我们还开发了一种新的多层次中介分析方法,可以进行纵向分析
对居住环境和个人风险因素进行评估,共同确定
种族与健康结果之间的机械联系。通过包括个人和环境的措施
因素,我们的方法能够解释健康结果中现有的差异。在这个项目中,我们的目标是
利用“我们所有人”项目收集的综合数据库来调查观察到的种族差异
乳腺癌的结果。使用新颖的多级中介分析方法,我们将识别可修改的
可以解释乳腺癌结果中观察到的种族差异的因素。应考虑的危险因素
考虑的措施包括环境(例如污染测量)和个人层面(例如
吸烟行为和基因表达)。这些信息将帮助护理人员设计精准医疗和
政策制定者评估旨在改善治疗和减少健康差距的干预措施。我们有
将我们的方法实现为 R 包 (mlma),为研究社区提供开放访问
用于执行多级中介分析的软件。我们计划进一步开发交互式网络的 API
实施该软件,以便所有研究人员无需编程即可使用该方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yaguang Xi其他文献
Yaguang Xi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yaguang Xi', 18)}}的其他基金
Developing LG007 as a novel therapeutic agent to treat triple negative breast cancer
开发 LG007 作为治疗三阴性乳腺癌的新型治疗剂
- 批准号:
10889411 - 财政年份:2023
- 资助金额:
$ 11.03万 - 项目类别:
Sulindac sensitizes colorectal cancer to anti-PD-L1 therapy
舒林酸使结直肠癌对抗 PD-L1 疗法敏感
- 批准号:
10889412 - 财政年份:2023
- 资助金额:
$ 11.03万 - 项目类别:
Interactions between ES-miRNAs and environmental risk factors are responsible for TNBC progression and associated racial health disparities: a novel analysis with multilevel moderation inferences
ES-miRNA 和环境风险因素之间的相互作用导致 TNBC 进展和相关种族健康差异:一项采用多级调节推论的新颖分析
- 批准号:
10594746 - 财政年份:2023
- 资助金额:
$ 11.03万 - 项目类别:
MiR-17 mediates sulindac anti-metastatic activity in human colorectal cancer
MiR-17 介导舒林酸在人结直肠癌中的抗转移活性
- 批准号:
10258119 - 财政年份:2022
- 资助金额:
$ 11.03万 - 项目类别:
Sulindac sensitizes colorectal cancer to anti-PD-L1 therapy
舒林酸使结直肠癌对抗 PD-L1 疗法敏感
- 批准号:
10538823 - 财政年份:2022
- 资助金额:
$ 11.03万 - 项目类别:
Developing LG007 as a novel therapeutic agent to treat triple negative breast cancer
开发 LG007 作为治疗三阴性乳腺癌的新型治疗剂
- 批准号:
10477444 - 财政年份:2021
- 资助金额:
$ 11.03万 - 项目类别:
Developing LG007 as a novel therapeutic agent to treat triple negative breast cancer
开发 LG007 作为治疗三阴性乳腺癌的新型治疗剂
- 批准号:
10313128 - 财政年份:2021
- 资助金额:
$ 11.03万 - 项目类别:
MicroRNA and colorectal cancer chemoprevention
MicroRNA 与结直肠癌化学预防
- 批准号:
9325302 - 财政年份:2015
- 资助金额:
$ 11.03万 - 项目类别:
MicroRNA and colorectal cancer chemoprevention
MicroRNA 与结直肠癌化学预防
- 批准号:
9313603 - 财政年份:2015
- 资助金额:
$ 11.03万 - 项目类别:
MicroRNA, a new player for the NSAID sulindac to prevent colon cancer progression
MicroRNA,NSAID 舒林酸预防结肠癌进展的新成员
- 批准号:
8707735 - 财政年份:2014
- 资助金额:
$ 11.03万 - 项目类别:
相似海外基金
Administrative Supplement: Improving Inference of Genetic Architecture and Selection with African Genomes
行政补充:利用非洲基因组改进遗传结构的推断和选择
- 批准号:
10891050 - 财政年份:2023
- 资助金额:
$ 11.03万 - 项目类别:
Addressing health disparities by providing evidence-based treatment in the Black Church
通过在黑人教会提供循证治疗来解决健康差异
- 批准号:
10721580 - 财政年份:2023
- 资助金额:
$ 11.03万 - 项目类别:
Using Re-inforcement Learning to Automatically Adapt a Remote Therapy Intervention (RTI) for Reducing Adolescent Violence Involvement
使用强化学习自动调整远程治疗干预 (RTI),以减少青少年暴力参与
- 批准号:
10834339 - 财政年份:2023
- 资助金额:
$ 11.03万 - 项目类别:
Role of early motor experience in infants with Down syndrome
早期运动经验对唐氏综合症婴儿的作用
- 批准号:
10531373 - 财政年份:2022
- 资助金额:
$ 11.03万 - 项目类别: